A joint research team from Russia and the U.K. has demonstrated the possibility of developing a new type of anti-neoplastic drugs based on nanoMIPs, or "plastic antibodies." NanoMIPs are synthetic polymers that can function as antibodies, selectively binding to target proteins on the surface of cancer cells. This approach could lead to a paradigm shift in the development of new methods for cancer treatment.
You are here
cientists have developed a technique that allows them to measure how well cancer drugs reach their targets inside the body. It shows individual cancer cells in a tumor in real time, revealing which cells interact with the drug and which cells the drug fails to reach.
In the future, the findings, published in Nature Communications, could help clinicians decide the best course and delivery of treatment for cancer patients.